The medical research sphere is highly competitive, the most recent, high profile, example of this was the Covid19 vaccine. If you snooze, you lose. And putting all our eggs into the ATH434 basket is a very risky strategy. If we don’t have the expertise to follow up on PBT2 as an antimicrobial agent, then employ someone (or multiple people) who does. Allocate resources to it. If that means a capital raising, then so be it.
ATH Price at posting:
2.0¢ Sentiment: Hold Disclosure: Held
